Collaboration and license agreements - Schedule of financial information related to collaboration and license agreements (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	$ 3,102	$ 11,799
Deferred revenue, current	18,712	15,471
Deferred revenue, net of current	28,457	21,814
Deferred Revenue, Total	47,169	37,285
MKDG Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	2,064
Deferred revenue, current	5,396
Deferred revenue, net of current	7,977
Deferred Revenue, Total	13,373
Merck Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	0	10,000
Deferred revenue, current	3,441	8,000
Deferred revenue, net of current	2,581	2,000
Deferred Revenue, Total	6,022	10,000
Betta Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	1,038	1,799
Deferred revenue, current	4,038	4,000
Deferred revenue, net of current	11,243	8,000
Deferred Revenue, Total	15,281	12,000
Roche Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	0	0
Deferred revenue, current	5,837	2,667
Deferred revenue, net of current	6,656	11,814
Deferred Revenue, Total	$ 12,493	14,481
Biogen Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable		0
Deferred revenue, current		804
Deferred revenue, net of current		0
Deferred Revenue, Total		$ 804